Transcript for FDA Media Briefing on HFA-propelled Albuterol Inhalers
Moderator: Christopher Kelly
May 30, 2008
1:00 pm CT
Welcome and thank you for standing by. All participants are currently in a
listen-only mode. To ask a question during the question and answer session,
please press star 1.
As a reminder, today's conference is being recorded. If you have any
objections, you may disconnect at this time.
I would now like to turn the conference over to your host, Mr. Christopher
Kelly. Sir, you may begin.
Christopher Kelly: Thank you (Sterling). Good afternoon everyone and thank you for joining us
on this call this afternoon. Today the U.S. Food and Drug Administration
issued a Public Health Advisory to alert patients, care givers and healthcare
professionals to switch to HFA-propelled albuterol inhalers because CFC-
propelled inhalers will not be available in the U.S. after December 31, 2008.
And I'd like to refer all of you to our news release that's posted on Website,
www.fda.gov and at the bottom of that news release is a link, which will take
you to a host of documents related to today's important announcement.
Joining me today is a panel of FDA experts who will discuss further the
actions that the FDA is taking in relation to this important announcement
On the panel is Deborah Henderson, a Senior Advisor to the Office of
Executive Programs for the Center for Drug Evaluation and Research for
FDA; Dr. Badrul Chowdhury, Director of the Division of Pulmonary and
Allergy Products for CDER, also with FDA; Dr. Sally Seymour, Medical
Team Leader, Division of Pulmonary and Allergy Products, CDER; and
Theresa Toigo, the Director of the Office of Special Health Issues with FDA.
I'd like to turn the program over now to Deborah Henderson who will speak
more about today's announcement. Debbie.
Deborah Henderson: Thank you Chris and thanks to all of you for joining us today. We are
particularly appreciative of the a